Related Experiment Video
Updated: Sep 17, 2025

Author Spotlight: Insight Into Advances in Prion Diseases Research
Published on: August 11, 2023
A review on current theories and potential therapies for prion diseases
Saranya Udayakumar1, Agnishwar Girigoswami1, Koyeli Girigoswami2
1Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chettinad Health City, Kelambakkam, Tamilnadu, 603103, India.
Abstract:
Prion diseases are neurodegenerative disorders that affect both humans and animals. They are commonly characterized by the absence of DNA and RNA and are distinguished from inherited or infectious forms. The cellular prion proteins (PrPC) misfold and accumulate into their pathogenic isoforms in these diseases. Disease conditions like Gerstmann-Straussler-Scheinker disease, Creutzfeldt-Jakob disease, and fatal familial insomnia are all related to prion proteins. The majority of the patients with prion disorders have a life expectancy of less than a year. An effective therapeutic approach for these prion diseases remains a formidable challenge. This review focuses on novel therapeutic approaches, such as antibody-based treatments that aim to stop normal proteins from changing into the harmful form of the prion protein (PrPSc). Additionally, the review discusses the potential of RNA interference, antisense oligonucleotides, anti-aggregation compounds, β-sheet breakers, and stem cell-based therapies in addressing prion diseases.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Parkinson's Disease: Overview
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...

